You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
SBC: GLYTR THERAPEUTICS, INC. Topic: 102AbstractTreatment of non-resectable recurrent/metastatic solid cancers is currently palliative only and there is an urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Antigen- targeting cancer immunotherapies such as bi-specific antibodies (eg Bi-specific T cell engager or BiTE’s) provide a unique approach for cancer immunotherapy. However, app ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Chondrofluid for arthroscopic knee cartilage repair
SBC: CARTILAGE INC Topic: NIAMSPROJECT SUMMARY Minor injuries to articular cartilage can initiate a catabolic cascade, causing small defects to progress into larger, more symptomatic defects. Pain, lesion progression, and accelerated joint deterioration may be avoided with strategies that repair small defects with hyaline-like cartilage. The repair of chondral defects using arthroscopic techniques, performed in a minimally inva ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced optics to unlock large field-of-view multiphoton imaging for neuroscience and beyond
SBC: PACIFICOPTICA LLC Topic: 101Project summary Currently available optical components limit biomedical imaging. In particular, in neurobiology, standard microscope components limit the field-of-view and speed of imaging of neuronal activity. Through prior work on BRAIN Initiative project, we have developed approaches for new optical components that expand the field-of-view 5 to 50 times over standard microscopes, with no loss i ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
SBC: TRIANGLE THERAPEUTICS INC. Topic: 300PROJECT SUMMARY Crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, pain, and weight loss. CD affects up to one million Americans and is a type of inflammatory bowel disease. CD is driven by CD4 T cells with a significant role for TH1 and TH17 cells and additional involvement of B cells. Current therapies for CD ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Integrated, Resilient, and Highly Adaptable Aerospace Information Networks
SBC: OWL Integrations, Inc. Topic: X22DOTCSO1United States Air Force S&T identifies five strategic capabilities: 1) Global Persistent Awareness, 2) Resilient Information Sharing, 3) Rapid, Effective Decision-Making, 4) Complexity, Unpredictability, and Mass, and 5) Speed and Reach of Disruption and
STTR Phase II 2023 Department of DefenseAir Force -
Demonstrating miniaturized production of a KOR PET tracer as a proof-of-concept for low-cost distribution of nascent PET neurotracers
SBC: DropletPharm Inc. Topic: NIDAPROJECT SUMMARY / ABSTRACT Positron-emission tomography (PET) studies play a critical role in many areas of neurological health by enabling quantitative in vivo measurements of specific neuroreceptor systems (e.g. receptor density, drug occupancy, endogenous ligand occupancy) to (i) evaluate fundamental hypotheses about disease or (ii) aid in the development of novel treatments targeting those rec ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of recombinant bovine lactoferrin and N-linked glycan effects on infant gut health and immunity
SBC: TURTLETREE LABS INC. Topic: NICHDProject Summary/Abstract Most infants currently rely on infant formula (IF) to meet their nutritional needs. However, existing infant formula is functionally inferior because it lacks breast milk bioactive proteins that are crucial to infant health and development. Consequently, formula-fed infants have increased risk of morbidity and mortality. Current technology limits the ability to add bioacti ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Precision Pointing for High Resolution Optical and RF Remote Sensing Satellites
SBC: K2 SPACE CORPORATION Topic: X22DOTCSO1K2 Space is developing the Giga Class satellite bus, an ultra-high-power spacecraft capable of delivering over 115kW of power and 15,000kg of payload mass to enable previously unattainable capabilities spanning ISR (Intelligence, Surveillance, and Reconna
STTR Phase II 2023 Department of DefenseAir Force -
Applying the FLiCert Design and Certification Support Tool to OEM eVTOL Applications
SBC: ADVANCED ROTORCRAFT TECHNOLOGY, INC. Topic: AFX20DTCSO1Through a previous AFWERX STTR Phase II contract, Advanced Rotorcraft Technology, Inc. (ART) has developed a high-fidelity simulation-based FLight Certification tool (FLiCert) for design, test, and certification support for Vertical Takeoff and Landing (V
STTR Phase II 2023 Department of DefenseAir Force -
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes
SBC: VALA SCIENCES, INC. Topic: NHLBICardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health